Literature DB >> 23602326

Favorable responses to tocilizumab in two patients with cancer-related cachexia.

Haruhiko Hirata, Satoshi Tetsumoto, Takashi Kijima, Hiroshi Kida, Toru Kumagai, Ryo Takahashi, Yasushi Otani, Koji Inoue, Hanako Kuhara, Kazuki Shimada, Izumi Nagatomo, Yoshito Takeda, Sho Goya, Kazuyuki Yoshizaki, Ichiro Kawase, Isao Tachibana, Tadamitsu Kishimoto, Atsushi Kumanogoh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23602326     DOI： 10.1016/j.jpainsymman.2013.01.009

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  20 in total

Review 1.  Role of interleukin-6 in cachexia: therapeutic implications.

Authors:  Aditi A Narsale; James A Carson
Journal:  Curr Opin Support Palliat Care       Date:  2014-12       Impact factor: 2.302

2.  Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.

Authors:  Kimbell L Hetzler; Justin P Hardee; Melissa J Puppa; Aditi A Narsale; Shuichi Sato; J Mark Davis; James A Carson
Journal:  Biochim Biophys Acta       Date:  2014-12-30

Review 3.  Nutrition challenges of cancer cachexia.

Authors:  Omnia U Gaafer; Teresa A Zimmers
Journal:  JPEN J Parenter Enteral Nutr       Date:  2021-11       Impact factor: 4.016

4.  Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.

Authors:  Melissa J Puppa; Song Gao; Aditi A Narsale; James A Carson
Journal:  FASEB J       Date:  2013-10-21       Impact factor: 5.191

5.  Type 2 immunity is maintained during cancer-associated adipose tissue wasting.

Authors:  Patrick J Lenehan; Assunta Cirella; Amiko M Uchida; Stephanie J Crowley; Tatyana Sharova; Genevieve Boland; Michael Dougan; Stephanie K Dougan; Max Heckler
Journal:  Immunother Adv       Date:  2021-06-02

Review 6.  Treatment of Cancer Pain by Targeting Cytokines.

Authors:  I Vendrell; D Macedo; I Alho; M R Dionísio; L Costa
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

7.  Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.

Authors:  Annamaria Ruzzo; Vincenzo Catalano; Emanuele Canestrari; Elisa Giacomini; Daniele Santini; Giuseppe Tonini; Bruno Vincenzi; Giammaria Fiorentini; Mauro Magnani; Francesco Graziano
Journal:  BMC Cancer       Date:  2014-05-22       Impact factor: 4.430

Review 8.  Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.

Authors:  Tae-Hwe Heo; Joseph Wahler; Nanjoo Suh
Journal:  Oncotarget       Date:  2016-03-29

9.  Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.

Authors:  Mariko Noguchi-Sasaki; Yusuke Sasaki; Yasushi Shimonaka; Kazushige Mori; Kaori Fujimoto-Ouchi
Journal:  BMC Cancer       Date:  2016-04-11       Impact factor: 4.430

10.  Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling.

Authors:  Kristine Pettersen; Sonja Andersen; Simone Degen; Valentina Tadini; Joël Grosjean; Shinji Hatakeyama; Almaz N Tesfahun; Siver Moestue; Jana Kim; Unni Nonstad; Pål R Romundstad; Frank Skorpen; Sveinung Sørhaug; Tore Amundsen; Bjørn H Grønberg; Florian Strasser; Nathan Stephens; Dag Hoem; Anders Molven; Stein Kaasa; Kenneth Fearon; Carsten Jacobi; Geir Bjørkøy
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.